NS-181 is a MetAP2 inhibitor and antiamebic agent with oral effectiveness.NS-181 functionally inhibits methionine aminopeptidase 2, a protein critical for Entamoeba histolytica proliferation. NS-181 exerts antiamebic activity against Entamoeba histolytica, leading to resolution of amebic liver abscess. NS-181 can be used for the research of amebiasis.

NLRP3-IN-89 is a NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. NLRP3-IN-89 inhibits the NLRP3 inflammasome pathway, reduces IL-1β secretion, and exhibits minimal interference with the NF-κB pathway. NLRP3-IN-89 can be used for the research of Parkinson's disease, frontotemporal dementia, multiple system atrophy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain injury.

JWG-045 is a selective ERK5 inhibitor. JWG-045 exhibits unique ferroptosis-resistant activity independent of ERK5 inhibition. JWG-045 can be used in breast cancer research.

JNK1 ligand-1 (Compound P1) is a selective JNK1 inhibitor. JNK1 ligand-1 can be used as a JNK1 ligand to synthesize a series of PROTAC molecules, such as PROTAC JNK1-targeted-1. PROTAC JNK1-targeted-1 can be used for the research of pulmonary fibrosis.

IP6K2-IN-1 is a selective flavonoid-based IP6K2 inhibitor with an IC50 value of 0.55 μM. IP6K2-IN-1 shows higher inhibitory potency against IP6K2 than IP6K1 and IP6K3. IP6K2-IN-1 can be utilised as a hit compound for further structural modifications of IP6K2 inhibitors.

iMQT_020 is a selective allosteric SLC1A5_var inhibitor. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism. iMQT_020 reduces GSH levels and increases cellular ROS and mitochondrial ROS. iMQT_020 induces apoptosis and ferroptosis. iMQT_020 can epigenetically upregulate PD-L1 expression. iMQT_020 can be used for the study of pancreatic cancer, lung cancer, and colon cancer.

HPK1-IN-64 is a potent, selective, and orally active HPK1 inhibitor with an IC50 value of 1.9 nM. HPK1-IN-64 exhibits selectivity exceeding 100-fold, 80-fold, 300-fold, and 350-fold against off-target kinases such as GLK, MAP4K5, TBK1, and TNIK, respectively. HPK1-IN-64 inhibits SLP76 protein phosphorylation and IL-2 secretion. HPK1-IN-64 may be used in cancer research, such as for colorectal cancer.

HDAC8-IN-16 is a selective histone deacetylase 8 (HDAC8) inhibitor with an IC50 of 0.16 μM. HDAC8-IN-16 induces cell apoptosis, triggers G2/M phase cell cycle arrest, and moderately inhibits cancer cell proliferation. HDAC8-IN-16 is applicable to relevant research on colorectal cancer.

HDAC6-IN-65 is a selective HDAC6 inhibitor (IC50 = 0.9 nM) and also exhibits a certain suppressive effect on HDAC3 (IC50 = 39.4 nM). HDAC6-IN-65 can induce the accumulation of α-tubulin (ac-tubulin) and acetylated histone H3 (ac-histone H3, a class I HDAC inhibition marker) in Neuro-2a cells. HDAC6-IN-65 can be used for the study of melanoma.

HDAC1/3-IN-1 is a selective HDAC1/3 inhibitor, with IC50 values of 256 nM and 340.3 nM against HDAC1 and HDAC3, respectively. HDAC1/3-IN-1 increases the SubG1 cell population and promotes apoptosis of glioma cells and glioblastoma stem cells. HDAC1/3-IN-1 can be used in studies related to glioblastoma.

HBC-12551 is an orally active BTK inhibitor (IC50 in HEK293 cells: 1.31 nM for BTK; 2.18 nM for BTKC481S). HBC-12551 has antitumor activity against diffuse large B-cell lymphoma.

GSK3-IN-11 is a Glycogen Synthase Kinase-3 (GSK-3) inhibitor with an IC50 of 5010 nM.

GPR6 inverse agonist 1 (Compound 101) is a selective GPR6 inverse agonist with an IC50 < 100 nM. GPR6 inverse agonist 1 is applicable to research related to Parkinson's disease and Huntington's disease.

Gd-PCTA-Ach is a macrocyclic gadolinium-based MRI contrast agent with high kinetic inertness and moderate albumin affinity. The albumin-binding property of Gd-PCTA-Ach effectively prolongs its blood circulation time. Gd-PCTA-Ach is mainly cleared via the kidneys, while approximately 10% of the dose is excreted through the hepatobiliary pathway, exhibiting a unique dual-channel excretion profile. Gd-PCTA-Ach enables high-quality imaging of brain and liver tumor lesions, and has important application value in diagnostic studies of liver cancer and glioma.

FAK activator-1 is a FAK activator and mucosal healing inducer.FAK activator-1 increases FAK phosphorylation at Tyr-397, promoting FAK activation.FAK activator-1 promotes mucosal healing.FAK activator-1 can be used for the research of nsaid-associated gastrointestinal mucosal injury.

FABP4/5-IN-6 is an orally active, potent FABP4/5 inhibitor (Ki = 0.41/2.53 μM), showing low selectivity over FABP3 (Ki = 59.72 μM). FABP4/5-IN-6 inhibits the secretion of MCP-1 and IL-6 in Lipopolysaccharides (LPS)-induced THP-1 macrophage. FABP4/5-IN-6 exhibits significant anti-inflammatory effects and attenuates LPS-induced liver injury. FABP4/5-IN-6 has low hERG inhibition (LD50 > 2000 mg/kg). FABP4/5-IN-6 can be used for the study of Inflammation-related diseases.

EL244 is a dua Autotaxin (ATX) (IC50 = 50 nM) inhibitor and PPARγ (IC50 = 1.3 μM; Kd = 1.3 μM) agonist. EL244 demonstrates low cytotoxicity in human HepG2 cells (EC50 = 81.2 μM) with minimal inhibition of the cardiac hERG potassium channel (12% at 25 μM). EL244 significantly reduces pulmonary Lysophosphatidic Acid (LPA) levels, attenuates fibrosis, and restores respiratory function with limited systemic absorption in vivo. EL244 can be used for idiopathic pulmonary fibrosis and interstitial lung disease (ILD) research.

EGFR-IN-77 (Compound 4a) is a selective EGFRT790M/L858R inhibitor, with an IC50 of 0.101 μM against EGFRT790M/L858R, 0.477 μM against EGFRL858R, and 1.771 μM against wild-type EGFR. EGFR-IN-77 functionally inhibits the kinase activities of EGFRT790M/L858R, EGFRL858R and wild-type EGFR. EGFR-IN-77 exerts selective antiproliferative effects on EGFRT790M/L858R non-small cell lung cancer cells. EGFR-IN-77 can be used for the research of EGFRL858R/T790M double-mutant non-small cell lung cancer.

EGFR-IN-204 (Example 1) is a HER2 exon 20 mutation inhibitor with selectivity for wild-type EGFR. EGFR-IN-204 exerts antiproliferative effects on cells dependent on HER2 exon 20 YVMA insertion mutation and wild-type HER2, and shows strong selectivity over cells dependent on wild-type EGFR. EGFR-IN-204 is applicable to non-small cell lung cancer research.

EG36 is a selective E. coli DnaK inhibitor that inhibits DnaK ATPase activity at a concentration of 100 μM. EG36 directly binds to the nucleotide-binding domain (NBD) of E. coli DnaK by disrupting the DnaK-DnaJ interaction. EG36 can be used for research on bacterial infectious diseases.

DOT1L705 is a PROTAC degrader that targets DOT1L. DOT1L705 recruits the VHL E3 ubiquitin ligase to induce proteasomal degradation of DOT1L. DOT1L705 reduces the viability of leukemia cells. DOT1L705 inhibits H3K79 methylation. DOT1L705 can be used in studies related to MLL-rearranged leukemia. (Pink: DOT1L ligand ; Blue: VHL E3 ligase ligand; Black: linker).

Discodermolide (NVP-XAA-296) is a potent microtubule-stabilizing agent with a Ki of 0.4 μM. Discodermolide stabilizes microtubules, induces G2 or M phase cell cycle arrest and apoptosis, leading to inhibition of cancer cell proliferation. Discodermolide competitively inhibits the binding of Paclitaxel to tubulin polymers, and inhibits the growth of Paclitaxel-resistant cells. Discodermolide can be used for breast and colon cancer research.

Desamino lenalidomide-5-F is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. Desamino lenalidomide-5-F can be linked to a target protein ligand via a linker to form a PROTAC.

D-DT/MIF-1-IN-1 (Compound 4h) is a non-competitive, non-covalent inhibitor of MIF-1 and D-DT, with IC50 values of 2.4 μM and 4.0 μM against D-DT, and an IC50 value of 9.8 μM against MIF-1. D-DT/MIF-1-IN-1 inhibits D-DT-induced phosphorylation of ERK and exerts antiproliferative activity in non-small cell lung cancer cells.

ddATP (2',3'-Dideoxyadenosine 5'-triphosphate), an active metabolite of 2',3'-dideoxyinosine, is a chain-elongating inhibitor of DNA polymerase. ddATP can be used for Sanger method for DNA sequencing and research of virus infection.

CYP51-IN-32 is an antifungal agent with an IC50 of 0.331 μM against CYP51 of Candida albicans. CYP51-IN-32 releases hydrogen sulfide (H2S) and inhibits hyphal formation and biofilm development of Candida albicans. CYP51-IN-32 can be formulated into PEG-based nanovesicles. CYP51-IN-32 is applicable to the research of Candida albicans infection.

CppA-IN-1 is a CppA inhibitor specific to Chlamydia trachomatis, which inhibits the growth of Chlamydia trachomatis. CppA-IN-1 shows no activity against recombinant CppA in vitro. CppA-IN-1 can be used in studies related to Chlamydia trachomatis infection.

CDK9-IN-49 is a CDK9 inhibitor with an IC50 of 7.32 nM. CDK9-IN-49 inhibits the proliferation of various cancer cells. CDK9-IN-49 can be used in the research of cancers such as acute myeloid leukemia and prostate cancer.

CDK2-IN-21 (example 30) is a potent cyclin-dependent kinase 2 (CDK2) inhibitor with an IC50 of 0.24 µM. CDK2-IN-21 can be used for cancer research.

CDC14A/B-IN-2, phosphotyrosine mimetic, is a competitive human CDC14A/B phosphatase inhibitor with IC50 values of 10.4 and 11.2 μM, and Ki values of 5.8 and 7.3 μM. CDC14A/B-IN-2 shows at least 20-fold selectivity over other protein tyrosine phosphatases. CDC14A/B-IN-2 can be used for the research of cancer.